182 related articles for article (PubMed ID: 8699233)
1. Immunohistochemical evaluation of erbB-2 and p53 protein expression in benign and atypical human meningiomas.
Chozick BS; Benzil DL; Stopa EG; Pezzullo JC; Knuckey NW; Epstein MH; Finkelstein SD; Finch PW
J Neurooncol; 1996 Feb; 27(2):117-26. PubMed ID: 8699233
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical study of Ki-67 (MIB-1), p53 protein, p21WAF1, and p27KIP1 expression in benign, atypical, and anaplastic meningiomas.
Amatya VJ; Takeshima Y; Sugiyama K; Kurisu K; Nishisaka T; Fukuhara T; Inai K
Hum Pathol; 2001 Sep; 32(9):970-5. PubMed ID: 11567227
[TBL] [Abstract][Full Text] [Related]
3. [Estrogen and progesterone receptors in meningiomas: immunohistochemical (Mib-1, p53) and clinico-morphological correlations].
Taddei GL; Caldarella A; Raspollini MR; Taddei A; Buccoliero AM
Pathologica; 2002 Feb; 94(1):10-5. PubMed ID: 11912872
[TBL] [Abstract][Full Text] [Related]
4. The significance of immunohistochemical expression of Ki-67, p53, p21, and p16 in meningiomas tissue arrays.
Terzi A; Saglam EA; Barak A; Soylemezoglu F
Pathol Res Pract; 2008; 204(5):305-14. PubMed ID: 18374497
[TBL] [Abstract][Full Text] [Related]
5. Different responses of benign and atypical meningiomas to gamma-knife radiosurgery: report of two cases with immunohistochemical analysis.
Kawashima M; Suzuki SO; Ikezaki K; Matsushima T; Fukui M; Iwaki T
Brain Tumor Pathol; 2001; 18(2):61-6. PubMed ID: 11908875
[TBL] [Abstract][Full Text] [Related]
6. [P53 protein expression and proliferative potential in non-recurrent and recurrent meningiomas].
Miyagami M; Kanou T; Nakamura S
No To Shinkei; 1996 Aug; 48(8):719-25. PubMed ID: 8797205
[TBL] [Abstract][Full Text] [Related]
7. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer.
Barbareschi M; Leonardi E; Mauri FA; Serio G; Dalla Palma P
Am J Clin Pathol; 1992 Oct; 98(4):408-18. PubMed ID: 1357956
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of p53 and p21WAF1/CIP1 immunoreactivity and tumor micronecrosis for recurrence of meningiomas.
Kamei Y; Watanabe M; Nakayama T; Kanamaru K; Waga S; Shiraishi T
J Neurooncol; 2000; 46(3):205-13. PubMed ID: 10902852
[TBL] [Abstract][Full Text] [Related]
9. Expression of the c-erbB-2-encoded oncoprotein and progesterone receptor in human meningiomas.
Schlegel J; Ullrich B; Stumm G; Gass P; Harwerth IM; Hynes NE; Kiessling M
Acta Neuropathol; 1993; 86(5):473-9. PubMed ID: 7906070
[TBL] [Abstract][Full Text] [Related]
10. Correlation between MIB-1 staining index and the immunoreactivity of p53 protein in recurrent and non-recurrent meningiomas.
Matsuno A; Nagashima T; Matsuura R; Tanaka H; Hirakawa M; Murakami M; Tamura A; Kirino T
Am J Clin Pathol; 1996 Dec; 106(6):776-81. PubMed ID: 8980354
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas.
Bozkurt SU; Ayan E; Bolukbasi F; Elmaci I; Pamir N; Sav A
APMIS; 2009 Sep; 117(9):651-9. PubMed ID: 19703125
[TBL] [Abstract][Full Text] [Related]
12. Malignant meningioma: a clinicopathologic study of 23 patients including MIB1 and p53 immunohistochemistry.
Prayson RA
Am J Clin Pathol; 1996 Jun; 105(6):719-26. PubMed ID: 8659446
[TBL] [Abstract][Full Text] [Related]
13. Expression of PDGF and its receptor as well as their relationship to proliferating activity and apoptosis of meningiomas in human meningiomas.
Yang SY; Xu GM
J Clin Neurosci; 2001 May; 8 Suppl 1():49-53. PubMed ID: 11386826
[TBL] [Abstract][Full Text] [Related]
14. Recurrence of benign meningiomas: predictive value of proliferative index, BCL2, p53, hormonal receptors and HER2 expression.
Abdelzaher E; El-Gendi SM; Yehya A; Gowil AG
Br J Neurosurg; 2011 Dec; 25(6):707-13. PubMed ID: 20979437
[TBL] [Abstract][Full Text] [Related]
15. Proliferative activity in breast carcinoma evaluated by BrdU and PCNA. Correlation with expression of p53, c-erbB-2, estrogen receptor and P-glycoprotein.
Moriki T; Takahashi T; Tanioka F; Yamane T; Hara H
Pathol Res Pract; 1995 Nov; 191(11):1122-32. PubMed ID: 8822114
[TBL] [Abstract][Full Text] [Related]
16. Meningiomas in Singapore: demographic and biological characteristics.
Das A; Tang WY; Smith DR
J Neurooncol; 2000 Apr; 47(2):153-60. PubMed ID: 10982157
[TBL] [Abstract][Full Text] [Related]
17. Role of p53 gene mutation in tumor aggressiveness of intracranial meningiomas.
Cho H; Ha SY; Park SH; Park K; Chae YS
J Korean Med Sci; 1999 Apr; 14(2):199-205. PubMed ID: 10331568
[TBL] [Abstract][Full Text] [Related]
18. [Expression of HER2/neu in meningiomas: an immunohistochemistry and fluorescence in situ hybridization study].
Wang CL; Mei JH; Wang SS; Xu S; Xu LL; Xiong YF
Zhonghua Bing Li Xue Za Zhi; 2010 Mar; 39(3):156-60. PubMed ID: 20450760
[TBL] [Abstract][Full Text] [Related]
19. Cathepsins B and L are markers for clinically invasive types of meningiomas.
Strojnik T; Zidanik B; Kos J; Lah TT
Neurosurgery; 2001 Mar; 48(3):598-605. PubMed ID: 11270551
[TBL] [Abstract][Full Text] [Related]
20. Merlin, DAL-1, and progesterone receptor expression in clinicopathologic subsets of meningioma: a correlative immunohistochemical study of 175 cases.
Perry A; Cai DX; Scheithauer BW; Swanson PE; Lohse CM; Newsham IF; Weaver A; Gutmann DH
J Neuropathol Exp Neurol; 2000 Oct; 59(10):872-9. PubMed ID: 11079777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
